NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals
NorthStar poised to be first commercial-scale supplier of important therapeutic radioisotopes Copper-67 (Cu-67) and Actinium-225 (Ac-225); Initial specialized SPECT imaging portfolio includes fibrin-targeted FibroScint, with potential indications in cardiovascular disease
March 16, 2021 NorthStar Medical Radioisotopes, LLC announced organizational changes to drive focused growth for its therapeutic and specialized single photon emission computed tomography (SPECT) radioisotopes business. The new structure enables NorthStar to advance its efforts in radioisotope development and commercialization planning in parallel with its ongoing expansion programs for increased U.S. molybdenum-99 (Mo-99) capacity and production.
In conjunction with other organizational changes, NorthStar has appointed Dave Wilson, RPh., BCNP, as Vice President, Advanced Radiopharmaceutical and Therapeuti
Search jobs 10-Mar-2021 IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Diagnostic Radioisotope Technetium-99m (Tc-99m)
IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Diagnostic Radioisotope Technetium-99m (Tc-99m)
− Collaboration enables integrating technology expertise to provide Tc-99m Generation Systems (TCM Generation Systems) that utilize non-uranium based Mo-99 produced using electron beam accelerators
− Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world
8
, 2021
–IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuti
Collaboration enables integrating technology expertise to provide Tc-99m Generation Systems (TCM Generation Systems) that utilize non-uranium based Mo-99 produced using electron beam accelerators
Columbia Daily Tribune
Under a new agreement, the University of Missouri Research Reactor will supply a radioisotope that serves as a key ingredient in a cancer therapy.
The multi-year agreement is with Advanced Accelerator Applications International, a Novartis pharmaceutical manufacturing company.
Since 2017, the research reactor has produced the radioisotope Lutetium-177 for the company under the name Lutathera. It is used to treat some tumors of the gastrointestinal tract and pancreas.
The new version of the radioisotope contains no trace of the long-lived isotope. That s a real benefit because hospitals won t have the same regulations for use, storage and disposal they have with the current version, said David Robertson, research reactor director.